Trombositten Zengin Plazmanın Tedavi Edici Etkisini Meloksikam ve Diklofenak Değiştirir Mi?

Abstract

The application of PRP is a common treatment modality in musculoskeletal injuries. Platelets are such cells containing much more growth factors and can secrete these factors inside the tissue by being activated and aggregated. Non-steroid antiinflammatory drugs (NSAIDs) are also being used for their antiinflammatory effects in musculoskeletal injuries. Some NSAIDs are known to inhibit the synthesis of Thromboxane A2 (TXA2) via the enzyme cyclooxygenase-1 (COX-1) inhibition and to have antiaggregant effects.Can synchronous treatment of PRP and NSAII change the therapeutic effect of PRP? In our study, blood was obtained from 20 healthy male volunteers and prepared PRP with Anitua technique described in the literature. Then PRPs were seperated into six groups and the groups are in order control, diclofenac minimum dose, diclofenac maximum dose, meloxicam minimum dose ,meloxicam maximum dose and acetylsalisilic acid groups. After exposure of drugs for 20 minutes for every group, 10% calcium chlorur was added for clotting and waited for 20 minutes. After then, the specimens were centrifuged for obtaining supernatants and supernatants were used for determination of platelet derived growth factor (PDGF)-AB and vascular endothelial growth factor (VEGF) amounts by ELISA methodology. The values for any groups has no statistical significant meaning (p>0,05). Finally, the mean amounts of PDGF-AB and VEGF in PRP’s prepared from diclofenac, meloxicam and acetylsalicylic added and no addiction (control) samples are similar for each groups.